ENANTA PHARMACEUTICALS, INC Operating Cash Flow
ENANTA PHARMACEUTICALS, INC (ENTA) reported Operating Cash Flow of -$28.83 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.97M, a 156.96% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$7.16M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.70M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.49M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2025 was -$19.27M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2024 was -$78.76M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2023 was -$103.15M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2022 was -$84.78M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | -$17.13M derived: sum of 2 quarters · filed 2026-08-12 | -$28.83M 10-Q · filed 2026-08-12 | -$35.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$7.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$18.86M 10-Q · filed 2026-05-13 | -$25.34M derived: sum of 3 quarters · filed 2026-05-13 | -$7.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$11.70M 10-Q · filed 2026-02-11 | -$18.19M derived: sum of 2 quarters · filed 2026-02-11 | -$682.00K derived: sum of 3 quarters · filed 2026-08-12 | -$14.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | -$6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $11.02M derived: sum of 2 quarters · filed 2026-08-12 | -$2.47M derived: sum of 3 quarters · filed 2026-08-12 | -$19.27M 10-K · filed 2025-11-19 |
| 2025-06-30 | $17.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $4.02M derived: sum of 2 quarters · filed 2026-08-12 | -$12.78M 10-Q · filed 2026-08-12 | -$23.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$13.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$30.29M 10-Q · filed 2026-05-13 | -$40.69M derived: sum of 3 quarters · filed 2026-05-13 | -$55.46M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$16.80M 10-Q · filed 2026-02-11 | -$27.20M derived: sum of 2 quarters · filed 2026-02-11 | -$41.98M derived: sum of 3 quarters · filed 2026-02-11 | -$70.58M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | -$10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$25.18M derived: sum of 2 quarters · filed 2025-11-19 | -$53.78M derived: sum of 3 quarters · filed 2025-11-19 | -$78.76M 10-K · filed 2025-11-19 |
| 2024-06-30 | -$14.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | -$43.38M derived: sum of 2 quarters · filed 2025-08-13 | -$68.36M 10-Q · filed 2025-08-13 | -$89.97M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | -$28.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | -$53.59M 10-Q · filed 2025-05-14 | -$75.19M derived: sum of 3 quarters · filed 2025-11-19 | -$107.32M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | -$24.99M 10-Q · filed 2025-02-12 | -$46.59M derived: sum of 2 quarters · filed 2025-11-19 | -$78.72M derived: sum of 3 quarters · filed 2025-11-19 | -$92.50M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | -$21.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$53.73M derived: sum of 2 quarters · filed 2025-11-19 | -$67.51M derived: sum of 3 quarters · filed 2025-11-19 | -$103.15M 10-K · filed 2025-11-19 |
| 2023-06-30 | -$32.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07 | -$45.91M derived: sum of 2 quarters · filed 2024-08-07 | -$81.55M 10-Q · filed 2024-08-07 | -$97.09M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | -$13.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | -$49.42M 10-Q · filed 2024-05-08 | -$64.96M derived: sum of 3 quarters · filed 2024-11-27 | -$94.56M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | -$35.64M 10-Q · filed 2024-02-08 | -$51.17M derived: sum of 2 quarters · filed 2024-11-27 | -$80.78M derived: sum of 3 quarters · filed 2024-11-27 | -$107.15M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | -$45.14M derived: sum of 2 quarters · filed 2024-11-27 | -$71.51M derived: sum of 3 quarters · filed 2024-11-27 | -$84.78M 10-K · filed 2024-11-27 |
| 2022-06-30 | -$29.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | -$55.98M derived: sum of 2 quarters · filed 2023-08-08 | -$69.25M 10-Q · filed 2023-08-08 | -$90.27M derived: sum of 4 quarters · filed 2023-11-22 |
| 2022-03-31 | -$26.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09 | -$39.65M 10-Q · filed 2023-05-09 | -$60.67M derived: sum of 3 quarters · filed 2023-11-22 | -$90.17M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-12-31 | -$13.27M 10-Q · filed 2023-02-08 | -$34.29M derived: sum of 2 quarters · filed 2023-11-22 | -$63.80M derived: sum of 3 quarters · filed 2023-11-22 | -$68.38M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-09-30 | -$21.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22 | -$50.53M derived: sum of 2 quarters · filed 2023-11-22 | -$55.11M derived: sum of 3 quarters · filed 2023-11-22 | -$70.00M 10-K · filed 2023-11-22 |
| 2021-06-30 | -$29.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | -$34.09M derived: sum of 2 quarters · filed 2022-08-08 | -$48.98M 10-Q · filed 2022-08-08 | -$64.44M derived: sum of 4 quarters · filed 2022-11-23 |
| 2021-03-31 | -$4.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09 | -$19.47M 10-Q · filed 2022-05-09 | -$34.93M derived: sum of 3 quarters · filed 2022-11-23 | -$39.42M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-12-31 | -$14.89M 10-Q · filed 2022-02-10 | -$30.35M derived: sum of 2 quarters · filed 2022-11-23 | -$34.84M derived: sum of 3 quarters · filed 2022-11-23 | -$20.16M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-09-30 | -$15.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | -$19.95M derived: sum of 2 quarters · filed 2022-11-23 | -$5.28M derived: sum of 3 quarters · filed 2022-11-23 | $7.09M 10-K · filed 2022-11-23 |
| 2020-06-30 | -$4.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $10.19M derived: sum of 2 quarters · filed 2021-08-09 | $22.55M 10-Q · filed 2021-08-09 | $31.09M derived: sum of 4 quarters · filed 2021-11-24 |
| 2020-03-31 | $14.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-10 | $27.04M 10-Q · filed 2021-05-10 | $35.58M derived: sum of 3 quarters · filed 2021-11-24 | $38.12M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-12-31 | $12.36M 10-Q · filed 2021-02-09 | $20.91M derived: sum of 2 quarters · filed 2021-11-24 | $23.44M derived: sum of 3 quarters · filed 2021-11-24 | $53.53M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-09-30 | $8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $11.08M derived: sum of 2 quarters · filed 2021-11-24 | $41.16M derived: sum of 3 quarters · filed 2021-11-24 | $71.42M 10-K · filed 2021-11-24 |
| 2019-06-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | $32.62M derived: sum of 2 quarters · filed 2020-08-10 | $62.87M 10-Q · filed 2020-08-10 | $91.21M derived: sum of 4 quarters · filed 2020-11-25 |
| 2019-03-31 | $30.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11 | $60.34M 10-Q · filed 2020-05-11 | $88.68M derived: sum of 3 quarters · filed 2020-11-25 | $92.73M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-12-31 | $30.25M 10-Q · filed 2020-02-10 | $58.59M derived: sum of 2 quarters · filed 2020-11-25 | $62.64M derived: sum of 3 quarters · filed 2020-11-25 | $55.06M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-09-30 | $28.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | $32.39M derived: sum of 2 quarters · filed 2020-11-25 | $24.81M derived: sum of 3 quarters · filed 2020-11-25 | $29.22M 10-K · filed 2020-11-25 |
| 2018-06-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | -$3.53M derived: sum of 2 quarters · filed 2019-08-09 | $879.00K 10-Q · filed 2019-08-09 | $58.19M derived: sum of 4 quarters · filed 2019-11-27 |
| 2018-03-31 | -$7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10 | -$3.17M 10-Q · filed 2019-05-10 | $54.14M derived: sum of 3 quarters · filed 2019-11-27 | |
| 2017-12-31 | $4.41M 10-Q · filed 2019-02-08 | $61.72M derived: sum of 2 quarters · filed 2019-11-27 | ||
| 2017-09-30 | $57.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | $52.65M 10-K · filed 2019-11-27 | ||
| 2017-06-30 | -$4.65M 10-Q · filed 2018-08-09 | |||
| 2016-09-30 | $35.81M 10-K · filed 2018-11-29 | |||
| 2014-03-31 | -$4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | -$10.00M 10-Q · filed 2014-05-12 | -$12.50M derived: sum of 3 quarters · filed 2014-05-12 | -$18.43M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | -$5.87M 10-Q · filed 2014-02-13 | -$8.37M derived: sum of 2 quarters · filed 2014-02-13 | -$14.30M derived: sum of 3 quarters · filed 2014-02-13 | -$4.26M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-09-30 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | -$8.43M derived: sum of 2 quarters · filed 2013-12-18 | $1.61M derived: sum of 3 quarters · filed 2014-05-12 | $10.65M 10-K · filed 2013-12-18 |
| 2013-06-30 | -$5.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | $4.11M derived: sum of 2 quarters · filed 2014-05-12 | $13.16M 10-Q · filed 2013-08-12 | $11.45M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-03-31 | $10.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | $19.08M 10-Q · filed 2014-05-12 | $17.38M derived: sum of 3 quarters · filed 2014-05-12 | $13.55M derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $9.04M 10-Q · filed 2014-02-13 | $7.34M derived: sum of 2 quarters · filed 2014-02-13 | $3.52M derived: sum of 3 quarters · filed 2014-02-13 | |
| 2012-09-30 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | -$5.53M derived: sum of 2 quarters · filed 2013-12-18 | $22.62M 10-K · filed 2013-12-18 | |
| 2012-06-30 | -$3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | $24.32M 10-Q · filed 2013-08-12 | ||
| 2012-03-31 | $28.15M 10-Q · filed 2013-05-15 | |||
| 2011-09-30 | $24.02M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |